, Volume 6, Issue 3, p 131
Date: 20 Aug 2011

Melanoma: a new landmark in targeted oncology

This is an excerpt from the content

The landscape of metastatic melanoma has been particularly dull for decades. The best response rate with classical chemotherapy dacarbazine has ranged from 6 to 28%, and survival has been absolutely disappointing. So it was a day to remember when the results of the BRIM III study were presented recently at the yearly American Society of Clinical Oncology (ASCO) meeting and published in the New England Journal of Medicine on the same day [1]. Six hundred and seventy five patients with Stage IIIc or Stage IV melanoma entered this study. All had been selected on the basis of the presence of an activating mutation of the BRAF gene (mutation V600). They were randomized to receive an anti-tyrosine kinase anti-Braf (vemurafenib) or dacarbazine. The results were very striking, with a reduction in the risk of death of 67% and a reduction in the risk of progression of 74% in the experimental arm when compared with the dacarbazine group.

This treatment stands as the first personalized treatment in ...